Pauls Dietrich John has filed 4 insider transactions across 1 company since June 2023.
Most recent transaction: a grant/award of 600000 shares of DiaMedica Therapeutics Inc. ($DMAC) on June 01, 2025.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 1, 2025 | DiaMedica Therapeutics Inc. | $DMAC | Pauls Dietrich John | President & CEO | A | Stock Option (right to buy) | 600000 | $0.00 | 600,000.0000 | 42,855,660 | 9999.99% | 1.40% |
| June 1, 2024 | DiaMedica Therapeutics Inc. | $DMAC | Pauls Dietrich John | President and CEO | A | Stock Option (right to buy) | 300000 | $0.00 | 300,000.0000 | 0 | 9999.99% | 0.00% |
| June 23, 2023 | DiaMedica Therapeutics Inc. | $DMAC | Pauls Dietrich John | President and CEO | P | Voting Common Shares, no par value per share | 12787 | $3.91 | 68,591.0000 | 0 | 22.91% | 0.00% |
| June 1, 2023 | DiaMedica Therapeutics Inc. | $DMAC | Pauls Dietrich John | President and CEO | A | Stock option (right to buy) | 181000 | $0.00 | 181,000.0000 | 0 | 9999.99% | 0.00% |